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A 12-year-old boy presented for treatment of
widespread papules and fungating, ulcerating
nodules (Fig 1). Seven months before referral, HIV
was diagnosed, and he started antiretroviral
therapy (ART), with a baseline CD4 count of
76 cells per microliter (5%). Per history, the
rash began 1 month after ART initiation and
progressively worsened in the 6 months after ART
therapy started. The patient was referred to the
Baylor Tanzania Center of Excellence in Mbeya,
Tanzania because of concern of possible Kaposi
sarcoma (KS).
A skin biopsy was performed. The patient
underwent chest radiography, abdominal ultrasound
scan, and liver/renal function tests, the results of
which were normal. A complete blood count was
notable for severe anemia (hemoglobin level of
4.0 g/dL) requiring blood transfusion. The clinical
diagnosis of bacillary angiomatosis (BA) was
favored, and the patient was prescribed doxycycline,
100 mg twice daily. Although KS was also in the
clinical differential diagnosis, chemotherapy was
withheld pending biopsy results. Histologically,
the lesion biopsy result was consistent with BA,
and bacilli were observed with Warthin-Starry
staining.
At the 1-week follow-up appointment, a dramatic
improvement in the appearance of the lesions was
noted (Fig 2). The patient continued doxycycline
with continued improvement over 7 additional
weeks, with near complete resolution of the sores
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enn.edu.DISCUSSION
BA is a rare multisystem bacterial infectious
vasculoproliferative disorder caused by Bartonella
henselae and Bartonella quintana and is most
commonly seen in HIV-infected individuals with
CD4 counts less than 200 cells per microliter.1 BA
commonly presents in the skin but may affect almost
any visceral organ, including liver, spleen, or nasal
cavity.2 Although there is no consensus treatment for
BA, clinicians experienced in treating this condition
recommend therapy with oral erythromycin or
doxycycline for 8 to 12 weeks to avoid relapses.3
KS is a rare angioproliferative opportunistic infec-
tion caused by human herpes virus 8 (HHV-8) also
seen in HIV-infected patients with low CD4 counts.
The overlapping constellation of cutaneous mani-
festations of BA and KS make them clinically
indistinguishable from each other when presenting
as single or multiple violaceous papules, nodules,
plaques or tumors.4 Occasionally, clinical clues can
lead toward one diagnosis or the other. KSmay cause
prominent lymphedema of the legs and oral lesions.
BA may have a very rapid onset with swift growth of
lesions, which may occur with immune reconstitu-
tion inflammatory syndrome, further complicatingJAAD Case Reports 2016;2:77-9.
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Fig 1. Clinical images from patient at presentation and after treatment with oral doxycycline.
This case shows BA presenting with widespread papules and fungating, ulcerating nodules
mimicking KS.
Fig 2. A dramatic improvement in the appearance of the cutaneous lesions was noted within
1 week of treatment with oral doxyxycline.
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without pathology. However, KS can also develop
rapidly in severely immunocompromised patients
and during immune reconstitution, and BA can
have oral lesions that mimic KS. In addition,
other HIV-associated dermatologic conditions,
such as disseminated mycobacterial or fungal
infections can have similar presentations to those
of KS or BA.
A study on the seroprevalence of HHV-8 in a
general population of Ugandan children suggeststhat infection with the virus often occurs during early
childhood and reaches a level of approximately 50%
before puberty.5 Tanzania, like other East African
countries, has a high HHV-8 seropositivity rate, with
one study estimating the prevalence of evidence of
HHV-8 infection to be 66% among adults.6 In
Malawian children, HIV infection has been
significantly associated with KS with an estimated
odds ratio of 93.5, emerging as one of the most
common pediatric cancers in sub-Saharan Africa in
the context of the HIV epidemic.7
Fig 3. The patient’s skin showed near complete resolution of the sores and lesions after
8 weeks of treatment with oral doxycycline.
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and the aggressive nature of KS, particularly in
children, health care providers in many regions of
Africa are often correct when they render a clinical
diagnosis of KS and begin chemotherapy, whereas
other potential diagnoses such as BA may not be
considered. The differentiation of BA and KS
histologically may still be difficult in early lesions,
particularly if HHV-8 immunostaining or Warthin-
Starry staining are not available. BA and KS can also
present simultaneously, further complicating the
clinical diagnosis, as antibiotic therapy may resolve
the BA but not treat the KS and associated systemic
symptoms. Conversely, BA lesions in a patient being
empirically treated with chemotherapy for KS may
initially respond because of the vascular nature of BA
lesions, but the lesions would likely not completely
resolve, creating a clinical quandary.8
A skin biopsy reviewed by a dermatopathologist
with special stains is necessary to definitively differ-
entiate between BA and KS; however, this is not
often available in the settings in which these patients
present. In those cases in which a patient cannot be
definitively diagnosed, and the clinical differential
diagnosis includes both BA and KS, we propose that
initial empiric treatment with erythromycin or
doxycycline may be a viable option. Although a
study assessing the efficacy of empiric erythromycin
or doxycycline therapy in cases such as this has not
yet been performed, both antibiotics are often
readily available, even in resource constrained
settings. If the patient does have BA, this therapy
typically leads to complete resolution of the BA with
minimal negative side effects and may result in a
response in as little as 7 days, as in the case of ourpatient. The rapid clearance of BA with doxycycline
observed by our patient is not unusual and has been
previously reported.9 Ultimately, if the patient does
not respond to empiric erythromycin or doxycycline,
the clinician may confidently proceed with treatment
for KS or other conditions.REFERENCES
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